Blood gene signals track bacterial load in pulmonary tuberculosis

Pulmonary tuberculosis (PTB) remains a global health challenge in part because measuring how much bacteria a person carries can be difficult. To better understand how the body’s immune system responds to different levels of bacteria, Nguyen Thuy Thuong Thuong and colleagues examined whole blood transcriptional responses associated with bacterial burden in people with PTB. They looked across patients with varying amounts of mycobacteria, including those with loads below the detection limit, to see which genes and immune pathways were turned on or off in the blood. Rather than focusing only on the bacteria in the lungs, the team searched for systemic signals — patterns of gene activity in whole blood — that correlate with how much bacteria a person is carrying before treatment. Their goal was to link pre-treatment bacterial burden with coordinated changes in the immune system, and to discover blood-based markers that could complement sputum tests or point to new treatment strategies.

Using analyses of whole blood transcriptional data, the researchers identified a coordinated module of immune pathways that distinguished patients with higher bacterial burden. Within this module, IFN-γ signaling appeared to play a central role in modulating the pattern: it was associated with an increase in innate signaling pathways (Toll-like, Nod-like receptors, TNF) and a simultaneous decrease in adaptive signaling (T- and B-cell receptor) in high-burden patients. The study found that these transcriptional responses were driven primarily by neutrophils and classical monocytes. At the level of individual genes, CNIH4 emerged as the strongest hub-gene and one of the top predictors of bacterial burden. Importantly, the predictive value of CNIH4 was consistently validated across independent PTB and TBM cohorts, strengthening the finding despite variation in bacterial loads, including loads below the detection limit.

These results have several important implications. First, they strengthen the biological link between pre-treatment mycobacterial burden and systemic immune dysregulation: higher bacterial burden is associated with coordinated upregulation of innate immune responses and downregulation of adaptive immune pathways. Second, the findings support the use of host transcriptomic profiling as a biologically informative complement to sputum-based measures of bacterial burden, offering a systemic readout that reflects immune dynamics. Third, by highlighting CNIH4 as a robust hub-gene and predictor of bacterial burden, the study points to a candidate biomarker that could be developed for treatment monitoring and possibly a target for host-directed therapeutic development. The work, supported by the National Institute of Health and the Wellcome Trust, UK, provides a clearer picture of how blood-based immune signals relate to bacterial load in PTB and related TB forms such as TBM.